Mineralys Therapeutics (MLYS) Treasury Shares (2022)

Mineralys Therapeutics has reported Treasury Shares for 4 years, with the latest figure at $125793.0 in Q4 2025.

• Quarterly Treasury Shares fell 66.01% year-over-year to $125793.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $125793.0 (down 66.01% YoY) and the FY2025 annual result came in at $125793.0, down 66.01% from the prior year.
• Treasury Shares eased to $125793.0 in Q4 2025 per MLYS's latest filing, from $370106.0 in the prior quarter.
• Over five years, Treasury Shares peaked at $136.5 million in Q2 2022 and troughed at $125793.0 in Q4 2025.
• A 4-year average of $60.1 million and a median of $43.7 million in 2022 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2023 and 2024: Treasury Shares slumped 98.83% in 2023, then plunged 63.28% in 2024.
• Over 4 years, Treasury Shares stood at $86.3 million in 2022, then plunged by 98.83% to $1.0 million in 2023, then slumped by 63.28% to $370106.0 in 2024, then sank by 66.01% to $125793.0 in 2025.
• According to Business Quant data, Treasury Shares over the past three periods registered $125793.0, $370106.0, and $1.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.